Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2019

View Archived Issues

Signature matching for PARP inhibitors

Melanocortin receptor signaling can cut both ways in obesity

Glycosylation controls proteasome activity via sequence editing

DDS-04a demonstrates potent antimicrobial activity against Enterobacteriaceae variants

Strengthening muscle cell production

Identification and targeting of an RNA-binding protein network in acute myeloid leukemia

Gene amplification leads to pathway addiction for NAD synthesis

Immunitor initiates phase II study of oral V-Boost vaccine to treat glioblastoma

VNRX-7145 has promising preclinical profile and is ready to enter phase I studies

IONIS-DGAT2RX shows safety and efficacy in phase II study

Cidara Therapeutics develops long-acting, bispecific antiviral Fc conjugate for influenza

Promising activity seen with DA-7310 in preclinical models of Gram-negative infection

FAK inhibitor APG-2449 enhances activity of antitumor agents

Development of novel hamster-L5 model to investigate pathophysiology of atherosclerosis

Chinese researchers patent BTK inhibitors

GlaxoSmithKline presents new RORC antagonists

Medshine Discovery and collaborator identify adenosine A2A receptor antagonists

GlaxoSmithKline discloses BRD4 inhibitors

Enrollment opens in phase I study of IMA-203 TCR-engineered T cells for solid tumors

Haplogen presents new PLA2 inhibitors

Scancell cleared to begin U.K. arm of SCIB-1 phase II trial in advanced melanoma

Forge Therapeutics, Basilea Pharmaceutica enter research collaboration to develop novel antibiotics

Selective and potent RAS inhibitor MCI-062 active against RAS-driven cancers

Emendo Biotherapeutics signs licensing agreement with Takeda Pharmaceutical for OMNI nuclear program

FDA accepts IND for AR-13503 sustained-release implant for wet AMD and DME

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...